Shares of Genmab A/S (NASDAQ:GMAB – Get Rating) have been given a consensus recommendation of "Hold" by the twelve brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $547.62.
Several equities analysts have recently weighed in on GMAB shares. TheStreet raised shares of Genmab A/S from a "c+" rating to a "b" rating in a research report on Wednesday, August 31st. SVB Leerink increased their price objective on shares of Genmab A/S from $30.00 to $31.00 and gave the company a "market perform" rating in a research report on Thursday, August 11th. Morgan Stanley increased their price objective on shares of Genmab A/S from $29.00 to $31.00 and gave the company an "underweight" rating in a research report on Monday, August 15th. HC Wainwright increased their price objective on shares of Genmab A/S from $49.00 to $51.00 and gave the company a "buy" rating in a research report on Monday, August 22nd. Finally, BMO Capital Markets began coverage on shares of Genmab A/S in a research note on Thursday, June 23rd. They issued a "market perform" rating and a $34.73 price target on the stock.
Get Genmab A/S alerts:Genmab A/S Trading Up 0.1 %
Shares of GMAB opened at $36.46 on Friday. Genmab A/S has a 12 month low of $26.19 and a 12 month high of $47.28. The firm has a fifty day simple moving average of $35.65 and a 200 day simple moving average of $33.88. The stock has a market capitalization of $23.99 billion, a price-to-earnings ratio of 40.51, a PEG ratio of 1.36 and a beta of 0.85.
Genmab A/S (NASDAQ:GMAB – Get Rating) last posted its quarterly earnings results on Wednesday, August 10th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.20. Genmab A/S had a net margin of 38.42% and a return on equity of 17.12%. The firm had revenue of $452.86 million for the quarter, compared to analyst estimates of $435.40 million. As a group, research analysts predict that Genmab A/S will post 1.02 earnings per share for the current fiscal year.Institutional Investors Weigh In On Genmab A/S
A number of hedge funds have recently made changes to their positions in the stock. Private Capital Group LLC raised its holdings in Genmab A/S by 14.1% in the 2nd quarter. Private Capital Group LLC now owns 2,677 shares of the company's stock valued at $87,000 after buying an additional 331 shares during the last quarter. Wetherby Asset Management Inc. raised its holdings in Genmab A/S by 2.6% in the 4th quarter. Wetherby Asset Management Inc. now owns 14,389 shares of the company's stock valued at $569,000 after buying an additional 358 shares during the last quarter. Private Advisor Group LLC raised its holdings in Genmab A/S by 2.0% in the 2nd quarter. Private Advisor Group LLC now owns 20,522 shares of the company's stock valued at $666,000 after buying an additional 403 shares during the last quarter. Cim LLC raised its holdings in Genmab A/S by 1.7% in the 1st quarter. Cim LLC now owns 27,994 shares of the company's stock valued at $1,002,000 after buying an additional 465 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in Genmab A/S by 9.3% in the 1st quarter. SG Americas Securities LLC now owns 6,050 shares of the company's stock valued at $219,000 after buying an additional 513 shares during the last quarter. 5.51% of the stock is currently owned by institutional investors and hedge funds.
About Genmab A/S
(Get Rating)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Read More
- Get a free copy of the StockNews.com research report on Genmab A/S (GMAB)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.